LiverRighttm, a Cincinnati-based provider of healthcare services for the U.S. Hepatology and Fatty Liver Disease communities, announced today that the LiverRight Hepatology Clinic has begun treating ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Weight-loss surgery can protect the liver health of patients with obesity and fatty liver disease, a new study repor ...

Study Uncovers Shortcomings in Pain Management for Preterm Babies in Intensive CareA large proportion of babies born very early need intensive care, ...

For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and ...

The liver is generally referred to as the detox powerhouse of the body. Its role in general health is so important that it ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...